- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT07592650
Applicability and Effectiveness of Remote Occupational Therapy
May 11, 2026 updated by: Battaglia Domenica Immacolata, Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Applicability and Effectiveness of Remote Occupational Therapy With Children and Adolescents With Dravet Syndrome and Their Families.
The pandemic has made it necessary to imagine and experiment with new ways for disabled patients to continue their care, responding to the sudden employment and emotional void of this historical period.
With this in mind, several studies have shown how telemedicine and telerehabilitation can represent a new frontier in care, reducing costs, shortening distances, increasing continuity of care, and also allowing services to be performed in a comfortable and familiar environment.
All these elements also combine to determine a positive effect on the patient's compliance with the therapeutic project, in which he or she finally feels like a protagonist.
It is evident that the application of these modalities in the pediatric patient requires the maximum cooperation from the family.
In this regard, it has been shown that despite the complexity associated with managing a patient with Dravet syndrome, families want to be involved, showing readiness to invest and participate in meaningful activities for their children.Considering the persistence of the national health emergency and the demonstrated effectiveness of remote occupational therapy in patients with behavioral and adaptive frameworks similar to Dravet patients, it is deemed interesting to test the feasibility of an occupational therapy project following the CO-OP approach (with the child or with the parent) also in this specific population.
Moreover, when considering the care gap given by the small number of recognized professionals in the field of occupational therapy and the uneven distribution of such a service across the territory at the expense of rural and disadvantaged areas, remote occupational therapy could be a significant resource for families of children and youth with disabilities even beyond the boundaries of the current COVID emergency.
Study Overview
Status
Completed
Conditions
Study Type
Observational
Enrollment (Actual)
14
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Rome, Italy, 00168
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
Accepts Healthy Volunteers
No
Sampling Method
Non-Probability Sample
Study Population
population selected from family association groups
Description
Inclusion Criteria:
- Diagnosis of Dravet Syndrome.
- Ages 7-18 years.
- Sufficient cognitive and behavioral skills to set goals and participate in treatment
- Access and manageability with respect to using a PC/tablet with a stable Internet connection
- Sufficient language/communication skills to follow simple instructions and interact with therapist
- Willingness/ability of a parent/caregiver in the family to attend all treatment sessions and involve themselves in "parent coaching." It will be necessary to maintain the same parent for the duration of the course.
Exclusion Criteria:
- Photosensitivity
- Organizational difficulties in the family that prevent the continuation of treatment
- Ongoing occupational treatment.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
|---|
|
Patients
Intervention Group 1 CO-OP with the patient
|
|
Parents
Intervention Group 2 CO-OP with the parents
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
effectiveness of a remote occupational therapy
Time Frame: 5 months
|
Evaluate the degree of improvement in self-perception of performance and satisfaction with goals achieved in therapy will be assessed during the clinical interview
|
5 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
cognitive-behavioral profile
Time Frame: 5 months
|
Evaluate the results of any effects of the rehabilitation intervention on the cognitive-behavioral profile of patients, thanks to the standardised tests.
|
5 months
|
|
adaptive behavior.
Time Frame: 5 months
|
Verify the effects of remote occupational therapy on patients' adaptive behavior in daily life activities, thanks to a questionnaire
|
5 months
|
|
QOLIE-31
Time Frame: 5 months
|
Verify the effects of remote occupational therapy on patients' and their families' quality of life thanks to a questionnaire.
|
5 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Domenica Immacolata Battaglia, Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
December 16, 2021
Primary Completion (Actual)
June 1, 2022
Study Completion (Actual)
January 2, 2023
Study Registration Dates
First Submitted
March 2, 2023
First Submitted That Met QC Criteria
May 11, 2026
First Posted (Actual)
May 18, 2026
Study Record Updates
Last Update Posted (Actual)
May 18, 2026
Last Update Submitted That Met QC Criteria
May 11, 2026
Last Verified
May 1, 2026
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 3982
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Dravet Syndrome
-
University Health Network, TorontoZogenix, Inc.Terminated
-
TakedaCompletedDravet Syndrome (DS)China, Canada, France, Hungary, Poland, United States, Spain, Greece, Australia, Brazil, Serbia, Germany, Italy, Japan, Latvia, Netherlands, Ukraine, Russian Federation
-
University of Colorado, DenverUCB PharmaRecruitingDravet Syndrome (DS) | Children Under 2 YearsUnited States
-
Alexander RotenbergA-SynapticNot yet recruitingDravet Syndrome (DS) | Lennox-Gastaut Syndrome (LGS)United States
-
TakedaCompletedDravet Syndrome (DS) | Lennox-Gastaut Syndrome (LGS)Spain
-
TakedaWithdrawnDravet Syndrome (DS) | Lennox-Gastaut Syndrome (LGS)
-
TakedaTerminatedDravet Syndrome (DS) | Lennox-Gastaut Syndrome (LGS)Denmark
-
TakedaTerminatedLennox Gastaut Syndrome (LGS) | Dravet Syndrome (DS)United States, China, Canada, France, Australia, Poland, Belgium, Spain, Hungary, Serbia, Greece, Japan, Latvia, Netherlands, Ukraine, Brazil, Mexico, Italy, Russia, Germany
-
TakedaTerminatedEpilepsy | Dravet Syndrome (DS) | Lennox-Gastaut Syndrome (LGS)United States, Canada, Australia, Israel, Poland, Spain, China, Portugal
-
Ionis Pharmaceuticals, Inc.RecruitingDravet SyndromeUnited States